{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:07:54Z","timestamp":1770905274516,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Although HER2 overexpression is observed in only 2%\u20133% of colorectal cancer (CRC) patients, its amplification can function as a compensatory mechanism that drives CRC resistance to targeted therapy. 1,2,3,4,6-Penta-O-galloyl-\u03b2-d-glucose (PGG) has been reported to possess anti-tumor and anti-metastatic activities in CRC. Nevertheless, the molecular targets through which PGG exerts its effects in CRC remain unclear. This study aimed to evaluate the role of HER2 as a potential molecular target of PGG in CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ultra performance liquid chromatography-mass spectrometer (UPLC-MS) was employed to determine the cellular uptake of PGG in HCT116 cells. Potential PGG targets were predicted using STITCH and molecular operating environment platforms. Functional rescue assays were performed with lapatinib, a HER2 inhibitor. Direct PGG\u2013HER2 interactions were validated by drug affinity responsive target stability and thermal shift assays. Downstream signaling effects were examined by assessing HER2 expression and its downstream pathway by Western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>UPLC-MS analysis confirmed the accumulation of PGG (204.5\u2009\u00b1\u200919.1\u00a0ng) in HCT116 cells after 40\u00a0\u03bcM PGG treatment for 12\u00a0h. Computational predictions suggested ErbB2 (HER2) as a potential binding target. Rescue experiments showed that the combination of lapatinib and PGG failed to further reduce cell viability when compared with lapatinib alone, implying HER2 as a molecular target of PGG. Both drug affinity responsive target stability and thermal shift assays verified that PGG protects HER2 from pronase-induced degradation and enhances its stability upon thermal challenge, indicating direct binding. Mechanistically, PGG suppressed HER2 expression and inhibited the PI3K-Akt-mTOR pathway, a canonical downstream pathway of HER2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings provide a strong preclinical rationale for future clinical trials of PGG as a HER2-targeted drug in CRC and highlight its considerable potential as a novel therapeutic for CRC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgaf098","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:26:25Z","timestamp":1760559985000},"source":"Crossref","is-referenced-by-count":0,"title":["Human epidermal growth factor receptor 2 as a target of 1,2,3,4,6-penta-\n                    <i>O<\/i>\n                    -galloyl-\n                    <b>\u03b2<\/b>\n                    -d-glucose in colon cancer"],"prefix":"10.1093","volume":"78","author":[{"given":"Huihai","family":"Yang","sequence":"first","affiliation":[{"name":"Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong , Shatin, New Territories, Hong Kong SAR ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Gar-Lee","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong , Pokfulam, Hong Kong SAR ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Chung","family":"Leung","sequence":"additional","affiliation":[{"name":"Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong , Shatin, New Territories, Hong Kong SAR ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-8331","authenticated-orcid":false,"given":"Chun-Kwok","family":"Wong","sequence":"additional","affiliation":[{"name":"Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong , Shatin, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Chemical Pathology, The Chinese University of Hong Kong , Shatin, New Territories, Hong Kong SAR ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences , Kunming 650000 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-1270","authenticated-orcid":false,"given":"Clara Bik-San","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong , Pokfulam, Hong Kong SAR ,","place":["China"]},{"name":"School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam , Hong Kong SAR ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026021208124700400_ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026021208124700400_ref2","doi-asserted-by":"publisher","first-page":"147857","DOI":"10.1016\/j.gene.2023.147857","article-title":"Colorectal cancer: genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials","volume":"892","author":"Housini","year":"2024","journal-title":"Gene"},{"key":"2026021208124700400_ref3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3748\/wjg.v29.i6.926","article-title":"Resistance to targeted therapy in metastatic colorectal cancer: current status and new developments","volume":"29","author":"Tang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026021208124700400_ref4","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.cbpa.2023.102401","article-title":"Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer","volume":"77","author":"Oliveres","year":"2023","journal-title":"Curr Opin Chem Biol"},{"key":"2026021208124700400_ref5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3748\/wjg.v29.i9.1395","article-title":"Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond","volume":"29","author":"Al Bitar","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026021208124700400_ref6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026021208124700400_ref7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamaoncol.2021.8196","article-title":"Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review","volume":"8","author":"Strickler","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026021208124700400_ref8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/jpm13121701","article-title":"Time to deliver on promises: the role of ERBB2 alterations as treatment options for colorectal cancer patients in the era of precision oncology","volume":"13","author":"Buchholz","year":"2023","journal-title":"J Personalized Med"},{"key":"2026021208124700400_ref9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026021208124700400_ref10","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.3390\/molecules28124856","article-title":"Pentagalloyl glucose: a review of anticancer properties, molecular targets, mechanisms of action, pharmacokinetics, and safety profile","volume":"28","author":"Wen","year":"2023","journal-title":"Molecules"},{"key":"2026021208124700400_ref11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bmcl.2018.05.028","article-title":"1,2,3,4,6-penta-O-galloyl-\u03b2-D-glucose suppresses colon cancer through induction of tumor suppressor","volume":"28","author":"Kawk","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"2026021208124700400_ref12","doi-asserted-by":"crossref","first-page":"106457","DOI":"10.1016\/j.phrs.2022.106457","article-title":"Anti-metastatic effects of 1,2,3,4,6-penta-O-galloyl-\u03b2-D-glucose in colorectal cancer: regulation of cathepsin B-mediated extracellular matrix dynamics and epithelial-to-mesenchymal transition","author":"Yang","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026021208124700400_ref13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1248\/cpb.50.841","article-title":"Two new acylated flavanone glycosides from the leaves and branches of Phyllanthus emblica","volume":"50","author":"Zhang","year":"2002","journal-title":"Chem Pharm Bull(Tokyo)"},{"key":"2026021208124700400_ref14","doi-asserted-by":"crossref","first-page":"D684","DOI":"10.1093\/nar\/gkm795","article-title":"STITCH: interaction networks of chemicals and proteins","volume":"36","author":"Kuhn","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"2026021208124700400_ref15","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1080\/07391102.2020.1803967","article-title":"Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2","volume":"39","author":"Khelfaoui","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"2026021208124700400_ref16","doi-asserted-by":"publisher","first-page":"1195883","DOI":"10.3389\/fchem.2023.1195883","article-title":"Discovery of a heat-generated compound DHD derived from Patrinia villosa water extract with inhibitory effects on colon cancer cells viability and migration","volume":"11","author":"Yang","year":"2023","journal-title":"Front Chem"},{"key":"2026021208124700400_ref17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11418-014-0823-2","article-title":"Biological and biomedical functions of penta-O-galloyl-D-glucose and its derivatives","volume":"68","author":"Cao","year":"2014","journal-title":"J Nat Med"},{"key":"2026021208124700400_ref18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/19768354.2022.2152864","article-title":"1,2,3,4,6-Penta-O-galloyl-\u03b2-D-glucose inhibits CD44v3, a cancer stem cell marker, by regulating its transcription factor, in human pancreatic cancer cell line","volume":"26","author":"Kim","year":"2022","journal-title":"Anim Cells Syst"},{"key":"2026021208124700400_ref19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fphar.2018.00065","article-title":"1,2,3,4,6-Penta-O-galloyl-\u03b2-D-glucopyranoside inhibits proliferation of multiple myeloma cells accompanied with suppression of MYC expression","volume":"9","author":"Tseeleesuren","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026021208124700400_ref20","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.3390\/molecules29215110","article-title":"Antioxidant 1,2,3,4,6-penta-O-galloyl-\u03b2-D-glucose alleviating apoptosis and promoting bone formation is associated with estrogen receptors","volume":"29","author":"Hua","year":"2024","journal-title":"Molecules"},{"key":"2026021208124700400_ref21","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026021208124700400_ref22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"key":"2026021208124700400_ref23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12094-019-02213-9","article-title":"Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer","volume":"22","author":"Wang","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2026021208124700400_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114798","article-title":"Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application","volume":"194","author":"Ren","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"2026021208124700400_ref25","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat Protoc"},{"key":"2026021208124700400_ref26","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1111\/bph.14823","article-title":"Andrographolide alleviates parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1","volume":"176","author":"Geng","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2026021208124700400_ref27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.apsb.2021.09.007","article-title":"Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK\/FOXO3a\/BIM-dependent manner","volume":"12","author":"Zheng","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"2026021208124700400_ref28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jcp.30655","article-title":"The PI3K\/Akt\/mTOR axis in colorectal cancer: oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles","volume":"3","author":"Sanaei","year":"2022","journal-title":"J Cell Physiol"},{"key":"2026021208124700400_ref29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"key":"2026021208124700400_ref30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026021208124700400_ref31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf098\/64711895\/rgaf098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf098\/64711895\/rgaf098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:12:57Z","timestamp":1770901977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgaf098\/8286966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaf098","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,15]]},"article-number":"rgaf098"}}